AGP Executive Report
Last update: 3 hours agoDrug safety in Europe: The EU Drugs Agency warns that Europe’s drug market is getting more complex and more dangerous, with 50 new psychoactive substances detected in 2025 (total: 1,050), rising use of highly potent synthetic opioids and stimulants, and more people mixing substances—plus concerns that some vapes may be used to deliver cannabinoids and other drugs. EU drug pricing pressure: Beneluxa countries urge deeper EU cooperation to keep medicine spending sustainable, as ministers meet in Luxembourg on June 16 and generics groups push faster off-patent alternatives. Luxembourg pharma logistics: DSV launched a direct Luxembourg–Indianapolis Air ThermoDirect route to strengthen cold-chain control for temperature-sensitive medicines, aiming to cut handling risk, emissions and uncertainty—an issue highlighted as pharma shifts toward personalised therapies. Local health funding: Luxembourg’s CNS finances could improve if the social security contribution cap for health insurance were lifted, with figures cited of €320m more revenue but also higher public costs. Public health risk in Luxembourg’s river: EMBL and the University of Luxembourg sampled the Moselle to study how pollution and environmental change may drive antimicrobial resistance.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
